MX338151B - Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. - Google Patents

Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.

Info

Publication number
MX338151B
MX338151B MX2011011163A MX2011011163A MX338151B MX 338151 B MX338151 B MX 338151B MX 2011011163 A MX2011011163 A MX 2011011163A MX 2011011163 A MX2011011163 A MX 2011011163A MX 338151 B MX338151 B MX 338151B
Authority
MX
Mexico
Prior art keywords
antibodies
antibody compositions
growth factor
factor receptor
epidermal growth
Prior art date
Application number
MX2011011163A
Other languages
English (en)
Inventor
Lucilla Steinaa
Klaus Koefoed
Per-Johan Meijer
Lars Soegaard Nielsen
Mikkel Wandahl Pedersen
Allan Jensen
Robert Carlsson
Charles Pyke
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39495833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338151(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Symphogen As filed Critical Symphogen As
Publication of MX338151B publication Critical patent/MX338151B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una composición de anticuerpos anti-EGFR caracterizada porque comprende al menos dos anticuerpos anti-EGFR distintos, en donde al menos uno de los anticuerpos anti-EGFR se selecciona de: (a) un anticuerpo que comprende CDR1, CDR2, y CDR3 de la cadena pesada de SEQ ID NO: 40 y CDR1, CDR2, y CDR3 de la cadena ligera de SEQ ID NO: 72 DE 992, y (b) un anticuerpo que comprende CDR1, CDR2, y CDR3 de la cadena pesada de SEQ ID NO: 41 y CDR1, CDR2, y CDR3 de la cadena ligera de SEQ LID NO: 73 DE 1024. Una composición farmacéutica que comprende la composición de anticuerpos anti-EGFR y un excipiente farmacéuticamente aceptable para usarse en la terapia del cáncer, en donde la composición está adaptada para ser administrable de forma simultánea, separada o sucesiva en la terapia del cáncer. Un anticuerpo aislado caracterizado porque comprende CDR1, CDR2, y CDR3 de la cadena pesada de SEQ ID NO: 40 y CDR1, CDR2, y CDR3 de la cadena ligera de SEQ ID NO: 72 de 992. Un anticuerpo aislado que comprende CDR1, CDR2, y CDR3 de la cadena pesada de SEQ ID NO: 41 y CDR1, CDR2, y CDR3 de la cadena ligera de SEQ ID NO:73 de 1,024.
MX2011011163A 2007-03-01 2008-02-27 Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. MX338151B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200700317 2007-03-01
US90477307P 2007-03-05 2007-03-05
DKPA200701016 2007-07-10
US92972707P 2007-07-11 2007-07-11
PCT/DK2008/050047 WO2008104183A2 (en) 2007-03-01 2008-02-27 Recombinant anti-epidermal growth factor receptor antibody compositions

Publications (1)

Publication Number Publication Date
MX338151B true MX338151B (es) 2016-04-05

Family

ID=39495833

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009008909A MX2009008909A (es) 2007-03-01 2008-02-27 Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
MX2011011163A MX338151B (es) 2007-03-01 2008-02-27 Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009008909A MX2009008909A (es) 2007-03-01 2008-02-27 Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.

Country Status (18)

Country Link
US (3) US7887805B2 (es)
EP (2) EP2132229B1 (es)
JP (1) JP5726417B2 (es)
KR (2) KR101805140B1 (es)
CN (2) CN104151430A (es)
AU (1) AU2008221118B2 (es)
BR (1) BRPI0808551B1 (es)
CA (1) CA2676049C (es)
DK (1) DK2132229T3 (es)
ES (1) ES2582386T3 (es)
HK (1) HK1197252A1 (es)
IL (2) IL199725A (es)
MX (2) MX2009008909A (es)
NZ (2) NZ597466A (es)
PL (1) PL2132229T3 (es)
RU (1) RU2013119724A (es)
TW (1) TWI426083B (es)
WO (1) WO2008104183A2 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ATE521704T1 (de) * 2007-03-01 2011-09-15 Symphogen As Verfahren zur klonierung verwandter antikörper
AU2008221118B2 (en) 2007-03-01 2013-10-03 Les Laboratoires Servier Recombinant anti-epidermal growth factor receptor antibody compositions
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
US20110256142A1 (en) * 2007-09-06 2011-10-20 Genmab A/S Novel methods and antibodies for treating cancer
US20090203038A1 (en) * 2007-12-27 2009-08-13 Abbott Laboratories Negative Mimic Antibody For Use as a Blocking Reagent In BNP Immunoassays
KR20110058861A (ko) * 2008-08-29 2011-06-01 심포젠 에이/에스 조류 유래 항체의 클로닝 방법
JP5719298B2 (ja) 2008-08-29 2015-05-13 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 組換え抗上皮増殖因子受容体抗体組成物
US20110224094A1 (en) * 2008-10-06 2011-09-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
FR2942928B1 (fr) 2009-03-03 2011-04-01 Alcatel Lucent Procede et systeme de gestion multicriteres de notifications de presence
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
AU2010305150A1 (en) * 2009-10-09 2012-04-05 Symphogen A/S Multiplex quantitation of individual recombinant proteins in a mixture by signature peptides and mass spectrometry
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
EP2563393B1 (en) * 2010-04-26 2016-06-08 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
WO2011140151A1 (en) * 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
MX2012012441A (es) * 2010-05-04 2013-02-26 Merrimack Pharmaceuticals Inc Anticuerpos contra el receptor del factor de crecimiento epidermico (egfr) y usos de los mismos.
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
EP2632490A4 (en) 2010-10-29 2014-10-22 Immunogen Inc NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
CN103328505B (zh) 2010-10-29 2015-12-02 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
US9217039B2 (en) * 2010-11-01 2015-12-22 Symphogen A/S Anti-HER3 antibodies and compositions
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
US10570211B2 (en) 2011-01-24 2020-02-25 Gilead Sciences, Inc. Antibodies selective for cells presenting EGFR at high density
WO2012122484A1 (en) 2011-03-09 2012-09-13 Roberto Polakiewicz Methods and reagents for creating monoclonal antibodies
CA2828075A1 (en) 2011-03-11 2012-09-20 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
MX2013010444A (es) 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
US20120258502A1 (en) * 2011-04-08 2012-10-11 Vinod Pandiripally Method of producing recombinant plasmid dna using substantially solid growth medium
US8691231B2 (en) * 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2012340686A1 (en) 2011-11-21 2014-06-19 Immunogen, Inc. Method of treatment of tumors that are resistant to EGFR therapies by EGFR antibody cytotoxic agent conjugate
CA2862979A1 (en) * 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US9527913B2 (en) 2012-05-02 2016-12-27 Symphogen A/S Humanized pan-HER antibody compositions
EP2894472A4 (en) * 2012-09-05 2016-03-30 Jsr Corp METHOD OF SCREENING MATERIAL FOR EPITHELIAL CONSERVATION OF CELLS
EP2912467A4 (en) * 2012-10-26 2016-04-20 Univ Queensland METHOD FOR CLASSIFYING TUMORS AND USE THEREOF
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
US9856319B2 (en) * 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
CN104059148B (zh) * 2013-03-18 2016-09-07 回而生医药科技（北京）有限公司 人源化抗人表皮生长因子受体抗体及其应用
KR20160055253A (ko) * 2013-09-12 2016-05-17 할로자임, 아이엔씨 변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
WO2015112749A2 (en) * 2014-01-22 2015-07-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
GB201402591D0 (en) 2014-02-14 2014-04-02 Memo Therapeutics Ag Method for recovering two or more genes, or gene products, encoding an immunoreceptor
DK3483593T3 (da) * 2014-03-26 2021-07-19 Siemens Healthcare Diagnostics Inc Luminescent-oxygen-channeling-immunoassay ved anvendelse af tre antistoffer og fremgangsmåder til fremstilling og anvendelse deraf
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
EP3223857A4 (en) * 2014-10-31 2018-06-27 Formation Biologics Inc. Egfr antibody-based combination therapy
SG11201706236SA (en) 2015-02-06 2017-08-30 Nat Univ Singapore Methods for enhancing efficacy of therapeutic immune cells
CA2983890A1 (en) 2015-04-24 2016-10-27 Merrimack Pharmaceuticals, Inc. Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies
BR112018068512A2 (pt) 2016-03-15 2019-01-22 Merrimack Pharmaceuticals Inc métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
CN109475627B (zh) * 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
AU2017363278B2 (en) 2016-11-22 2022-10-27 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
WO2018119402A1 (en) * 2016-12-23 2018-06-28 Visterra, Inc. Binding polypeptides and methods of making the same
WO2018152634A1 (en) * 2017-02-22 2018-08-30 University Of Saskatchewan Egfr-binding agents and uses thereof
WO2018166119A1 (zh) * 2017-03-14 2018-09-20 北京伟峰益民科技有限公司 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用
AU2018313939A1 (en) 2017-08-10 2020-02-06 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
CN111278992A (zh) 2017-08-30 2020-06-12 西福根有限公司 用抗egfr抗体治疗癌症的组合物和方法
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
MX2020007880A (es) * 2018-01-25 2021-05-14 Cullinan Mica Corp Anticuerpos de mica/b y metodos de uso.
AU2019275076B2 (en) 2018-05-23 2024-12-19 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
US11274035B2 (en) 2019-04-24 2022-03-15 X-Celeprint Limited Overhanging device structures and related methods of manufacture
US12162747B2 (en) 2018-12-03 2024-12-10 X-Celeprint Limited Enclosed cavity structures
US10456776B1 (en) 2019-02-21 2019-10-29 King Saud University Method of fabricating a photocatalyst for water splitting
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN111018990A (zh) * 2020-02-10 2020-04-17 张喜田 一种新型的重组抗表皮生长因子受体单克隆抗体及其应用
MX2024004145A (es) 2021-10-04 2024-04-22 Servier Lab Terapia del cancer dirigida a nkg2a.
AR127893A1 (es) 2021-12-10 2024-03-06 Servier Lab Terapia del cáncer dirigida a egfr

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
CZ282603B6 (cs) * 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1432064A (zh) 2000-03-23 2003-07-23 格林维尔医院系统公司 双功能癌症治疗剂
ES2259030T3 (es) * 2000-05-19 2006-09-16 Scancell Limited Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico.
US6849259B2 (en) * 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
WO2002066058A1 (en) * 2001-02-19 2002-08-29 Merck Patent Gmbh Modified anti-egfr antibodies with reduced immunogenicity
PT1392359E (pt) 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
RU2335507C2 (ru) 2001-06-13 2008-10-10 Генмаб А/С Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2002326531A1 (en) * 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
AU2003211342A1 (en) * 2002-03-01 2003-09-16 Japan Envirochemicals, Ltd. Proteins capable of binding to environmental hormones and process for producing the same
EP1511769A2 (en) 2002-05-15 2005-03-09 Birgit Luber Egf receptor antagonists in the treatment of gastric cancer
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
ATE535254T1 (de) 2002-07-15 2011-12-15 Genentech Inc Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
AU2003276084B2 (en) * 2002-10-10 2009-07-09 Merck Patent Gmbh Bispecific anti-Erb-B antibodies and their use in tumor therapy
DK1583830T3 (da) 2003-01-07 2007-01-15 Symphogen As Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
CA2554195C (en) 2004-01-23 2011-02-22 Green Peptide Co., Ltd. Peptide originating in epidermal growth factor receptor (egfr)
US20110142822A1 (en) 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
RU2426795C2 (ru) * 2004-07-20 2011-08-20 Симфоген А/С Способ структурной характеристики рекомбинантного поликлонального белка или поликлональной клеточной линии
BRPI0513706A (pt) 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
MX2007009889A (es) 2005-02-23 2007-09-07 Genentech Inc Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer.
CA2601936C (en) 2005-02-24 2014-06-17 Amgen Inc. Epidermal growth factor receptor mutations
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2006110478A2 (en) 2005-04-11 2006-10-19 Novartis Ag Mutations and polymorphisms of epidermal growth factor receptor
JP2008535508A (ja) 2005-04-14 2008-09-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 腫瘍組織における増大したコピー数のｅｇｆｒ遺伝子に基づく抗ｅｇｆｒ抗体療法
EP1877083A2 (en) 2005-04-27 2008-01-16 Welson Pharmaceuticals, Inc. Antibodies for the treatment of cancers
KR101888321B1 (ko) * 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20070036786A1 (en) * 2005-07-11 2007-02-15 Nadine Tuaillon Method of treating autoimmune disease using humanized anti-CD16A antibodies
EP2314619A1 (en) * 2005-12-05 2011-04-27 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
CA2638833A1 (en) 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
AU2008221118B2 (en) 2007-03-01 2013-10-03 Les Laboratoires Servier Recombinant anti-epidermal growth factor receptor antibody compositions
ATE521704T1 (de) 2007-03-01 2011-09-15 Symphogen As Verfahren zur klonierung verwandter antikörper
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
JP5719298B2 (ja) * 2008-08-29 2015-05-13 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 組換え抗上皮増殖因子受容体抗体組成物
US9155802B2 (en) * 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition

Also Published As

Publication number Publication date
TWI426083B (zh) 2014-02-11
IL199725A0 (en) 2010-04-15
AU2008221118B2 (en) 2013-10-03
IL216850A (en) 2014-06-30
BRPI0808551A2 (pt) 2014-08-19
ES2582386T3 (es) 2016-09-12
CN104151430A (zh) 2014-11-19
HK1134826A1 (zh) 2010-06-11
KR101676622B1 (ko) 2016-11-17
WO2008104183A2 (en) 2008-09-04
KR20100014722A (ko) 2010-02-10
CN101675075A (zh) 2010-03-17
US20110129855A1 (en) 2011-06-02
HK1197252A1 (en) 2015-01-09
EP2725036A1 (en) 2014-04-30
JP2010535012A (ja) 2010-11-18
US7887805B2 (en) 2011-02-15
IL216850A0 (en) 2012-01-31
CA2676049C (en) 2018-04-10
CA2676049A1 (en) 2008-09-04
US20110135636A1 (en) 2011-06-09
KR101805140B1 (ko) 2017-12-05
DK2132229T3 (en) 2016-06-20
WO2008104183A3 (en) 2008-11-13
AU2008221118A1 (en) 2008-09-04
NZ597466A (en) 2013-08-30
EP2132229A2 (en) 2009-12-16
NZ578943A (en) 2012-09-28
US8414896B2 (en) 2013-04-09
US20090004192A1 (en) 2009-01-01
CN101675075B (zh) 2014-06-18
KR20160132132A (ko) 2016-11-16
EP2132229B1 (en) 2016-05-11
RU2013119724A (ru) 2014-11-10
TW200902552A (en) 2009-01-16
IL199725A (en) 2015-06-30
PL2132229T3 (pl) 2016-12-30
EP2725036B1 (en) 2017-10-25
BRPI0808551B1 (pt) 2022-04-05
MX2009008909A (es) 2009-08-28
JP5726417B2 (ja) 2015-06-03

Similar Documents

Publication Publication Date Title
MX2009008909A (es) Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
NZ599875A (en) Human il-23 antigen binding proteins
WO2010022736A3 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
MY185858A (en) Specific binding proteins and uses thereof
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
MX2010001757A (es) Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
NZ596490A (en) Monoclonal antibodies that bind GT468 for the treatment of cancer
MX2013007067A (es) Anticuerpos anti-il-18 y sus usos.
PH12012501720A1 (en) Therapeutic dll4 binding proteins
MX2010008060A (es) Anticuerpos humanizados especificos para el factor von willerbrand.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2011143318A3 (en) Anti-fgfr2 antibodies
PH12012502022B1 (en) Anti-erbb3 antibodies
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
JO3291B1 (ar) الأجسام المضادة لـ csf-1r
WO2015108998A3 (en) Cartilage targeting agents and their use
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2010080248A3 (en) Peptides that bind eukaryotic translation initiation factor 4e